# Linking hypoxia-inducible factor (HIF)-1α and HIF-2α expression in head and neck cancer

## TL;DR

This study examines how HIF-1α and HIF-2α protein levels in head and neck cancer tissues relate to patient outcomes.

## Contribution

The study links elevated HIF-1α and HIF-2α expression to worse clinical outcomes in head and neck cancer patients.

## Key findings

- Higher HIF-1α and HIF-2α expression correlates with worse clinical outcomes in HNSCC patients.
- Immunohistochemistry was used to categorize HIF expression levels as low, moderate, or high.
- Hypoxia-inducible factors are associated with tumor progression and therapeutic resistance in head and neck cancer.

## Abstract

Hypoxic conditions often occur in solid tumors like those of the head and neck area, thus enhancing tumor evolution while causing
both therapeutic resistance and worsening clinical outcomes. Therefore, it is of interest to evaluate the expression of HIF-1α and
HIF-2α proteins to correlate with clinical outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Hence, 80
patients with HNSCC participated in this study. The laboratory analysis of tumor tissue, conducted through immunohistochemistry,
revealed the expression levels of HIF-1α and HIF-2α. The examined tissues were categorized into low, moderate, and high
expression categories based on immunoreactivity scoring. The clinical outcomes of head and neck cancer patients become worse when
producers of HIF-1α and HIF-2α elevate in their tumors.